Drexel University’s School of Biomedical Engineering, Science and Health Systems was awarded nearly $1 million from New Jersey biopharmaceutical company Bristol-Myers Squibb to support the creation of a new cell and gene therapy academic program.
Drexel rolled out the curriculum as a 30 credit concentration for undergraduate or graduate students at the biomedical school this summer and expects to launch it as a minor after the initial trial period.
The coursework will include cell and gene therapy manufacturing, regulatory requirements, analytical techniques, immune engineering, genomics and informatics taught by faculty at the School of Biomedical Engineering.